搜索结果: 'mtesr plus'

Brochure
Modeling Cystic Fibrosis Airway: PneumaCult™-Ex Plus and PneumaCult™-ALI

产品类型：

Cell Culture Media and Supplements

品牌：

PneumaCult

产品号#：

05001

05021

05022

38023

38024

05040

00218CA.2

产品名：

PneumaCult™阿里介质

PneumaCult™阿里介质

PneumaCult™阿里介质

Costar®12 mm Transwell®，0.4 µm孔径的聚酯膜小室插件

Costar®6.5 mm Transwell®，0.4µm孔径的聚酯膜小室插件

PneumaCult™-Ex Plus Medium

人呼吸道上皮细胞课程 - CA - 秋季
Brochure
Modeling Cystic Fibrosis Airway: PneumaCult™-Ex Plus and PneumaCult™-ALI

产品类型：

Cell Culture Media and Supplements

品牌：

PneumaCult

产品号#：

05001

05021

05022

38023

38024

05040

00218CA.2

产品名：

PneumaCult™阿里介质

PneumaCult™阿里介质

PneumaCult™阿里介质

Costar®12 mm Transwell®，0.4 µm孔径的聚酯膜小室插件

Costar®6.5 mm Transwell®，0.4µm孔径的聚酯膜小室插件

PneumaCult™-Ex Plus Medium

人呼吸道上皮细胞课程 - CA - 秋季
技术手册
Corning® Lambda® Plus Single-channel, 8-channel, and 12-channel Pipettors

产品类型：

产品号#：

38058

38059

38060

38061

38062

38063

38064

产品名：

Corning®Lambda™ Plus 移液器, 1000 µL

Corning®Lambda™ Plus 移液器, 200 µL

Corning®Lambda™ Plus 移液器, 20 µL

Corning®Lambda™ Plus 移液器, 10 µL

Corning®Lambda™ Plus 移液器, 2 µL

Corning®Lambda™ Plus 移液器启动套装

Corning®Lambda™Plus 12通道移液器, 200 µL
Brochure
Redefine Intestinal Organoid Culture: IntestiCult™ Plus Organoid Growth Medium

产品类型：

Cell Culture Media and Supplements

品牌：

IntestiCult

产品号#：

产品名：
Brochure
PneumaCult™-Ex Plus: Generate More Airway Epithelial Cells for Extended Passages

产品类型：

Cell Culture Media and Supplements

品牌：

PneumaCult

产品号#：

05001

05021

05022

05040

产品名：

PneumaCult™阿里介质

PneumaCult™阿里介质

PneumaCult™阿里介质

PneumaCult™-Ex Plus Medium
文献

S. Badrinath et al. (jun 2022) Nature 606 7916 992--998

A vaccine targeting resistant tumours by dual T cell plus NK cell attack.

Most cancer vaccines target peptide antigens,necessitating personalization owing to the vast inter-individual diversity in major histocompatibility complex (MHC) molecules that present peptides to T cells. Furthermore,tumours frequently escape T cell-mediated immunity through mechanisms that interfere with peptide presentation1. Here we report a cancer vaccine that induces a coordinated attack by diverse T cell and natural killer (NK) cell populations. The vaccine targets the MICA and MICB (MICA/B) stress proteins expressed by many human cancers as a result of DNA damage2. MICA/B serve as ligands for the activating NKG2D receptor on T cells and NK cells,but tumours evade immune recognition by proteolytic MICA/B cleavage3,4. Vaccine-induced antibodies increase the density of MICA/B proteins on the surface of tumour cells by inhibiting proteolytic shedding,enhance presentation of tumour antigens by dendritic cells to T cells and augment the cytotoxic function of NK cells. Notably,this vaccine maintains efficacy against MHC class I-deficient tumours resistant to cytotoxic T cells through the coordinated action of NK cells and CD4+ T cells. The vaccine is also efficacious in a clinically important setting: immunization following surgical removal of primary,highly metastatic tumours inhibits the later outgrowth of metastases. This vaccine design enables protective immunity even against tumours with common escape mutations. View Publication

产品类型：

产品号#：

产品名：
文献

Hoeflich KP et al. ( 2012) Cancer research 72 1 210--219

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.

Combinations of MAP/ERK kinase (MEK) and phosphoinositide 3-kinase (PI3K) inhibitors have shown promise in preclinical cancer models,leading to the initiation of clinical trials cotargeting these two key cancer signaling pathways. GDC-0973,a novel selective MEK inhibitor,and GDC-0941,a class I PI3K inhibitor,are in early stage clinical trials as both single agents and in combination. The discovery of these selective inhibitors has allowed investigation into the precise effects of combining inhibitors of two major signaling branches downstream of RAS. Here,we investigated multiple biomarkers in the mitogen-activated protein kinase (MAPK) and PI3K pathway to search for points of convergence that explain the increased apoptosis seen in combination. Using washout studies in vitro and alternate dosing schedules in mice,we showed that intermittent inhibition of the PI3K and MAPK pathway is sufficient for efficacy in BRAF and KRAS mutant cancer cells. The combination of GDC-0973 with the PI3K inhibitor GDC-0941 resulted in combination efficacy in vitro and in vivo via induction of biomarkers associated with apoptosis,including Bcl-2 family proapoptotic regulators. Therefore,these data suggest that continuous exposure of MEK and PI3K inhibitors in combination is not required for efficacy in preclinical cancer models and that sustained effects on downstream apoptosis biomarkers can be observed in response to intermittent dosing. View Publication

产品类型：

产品号#：

73152

产品名：

GDC-0941
文献

Gerson SL et al. (SEP 1996) Blood 88 5 1649--55

Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU.

Human bone marrow (BM) cells contain low levels of the DNA repair protein,O6-alkylguanine-DNA alkyltransferase,which may explain their susceptibility to nitrosourea-induced cytotoxicity and the development of secondary leukemia after nitrosourea treatment. Isolated CD34+ myeloid progenitors were also found to have low levels of alkyltransferase activity. The level of alkyltransferase in CD34+ cells or in mononuclear BM cells did not increase after incubation with granulocyte-macrophage colony-stimulating factor,interleukin-3,stem cell factor,the combination,or 5637 conditioned medium. BCNU sensitivity remained unchanged as well. In addition,O6-benzylguanine depleted alkyltransferase activity in BM cells at concentrations as low as 1.5 mumol/L after a 1-hour exposure. O6-benzylguanine pretreatment markedly sensitized hematopoietic progenitor colony-forming cells to BCNU,resulting in a reduction in the dose of drug (termed the dose-modification factor) required to inhibit 50% of the colony formation (IC50) of threefold to fivefold. Since,unlike many other cell types,proliferating early (CD34+) hematopoietic precursors do not induce alkyltransferase,myelosuppression may be the dose-limiting toxicity of the combination of O6-benzylguanine plus BCNU in clinical trials. View Publication

产品类型：

产品号#：

73762

产品名：

O6 -苄基鸟嘌呤（Benzylguanine）
科学海报
PneumaCult™-Ex Plus, a Novel Defined and Feeder-Free Medium, Supports the Improved Expansion of Primary Human Airway Epithelial Cells

产品类型：

Cell Culture Media and Supplements

Conference：

American Thoracic Society Conference 2017

产品号#：

05040

78161.1

78174

78174.1

78173.1

78173.2

产品名：

PneumaCult™-Ex Plus Medium

重组人FGF-9

重组人TGF - β 2

重组人TGF - β 2

重组人FGF-10 （KGF-2），ACF

重组人FGF-10 （KGF-2），ACF
文献

Galera-Monge T et al. (MAY 2016) Stem Cell Research 16 3 673--676

Generation of a human iPSC line from a patient with an optic atrophy ‘plus' phenotype due to a mutation in the OPA1 gene

Human iPSC line Oex2054SV.4 was generated from fibroblasts of a patient with an optic atrophy 'plus' phenotype associated with a heterozygous mutation in the OPA1 gene. Reprogramming factors OCT3/4,SOX2,CMYC and KLF4 were delivered using a non-integrative methodology that involves the use of Sendai virus. View Publication

产品类型：

产品号#：

85850

85857

产品名：

mTeSR™1

mTeSR™1
技术窍门
mTeSR™3D: Clump Passaging Method for Suspension Culture hPSCs

产品类型：

Cell Culture Media and Supplements

细胞类型：

多能干细胞

产品号#：

03950

产品名：

mTeSR™3D
Scalable Enzyme-Free Passaging of Human Pluripotent Stem Cells Cultured in mTeSR™1 or TeSR™-E8™ Without Scraping

产品类型：

Conference：

ISSCR 2014

产品号#：

产品名：